← boardnext 2026-08next 2026-09next 2026-09next 2026-10
CORT
Corcept Therapeuticsdistress 0/10 · well-funded / low risk$92.98+2%today-3% from 52w high
Metabolic / Obesity 1Oncology 1
Lead: platinum-resistant ovarian cancer · est. market ~$8B (approx, global)
Revenue
$165M
Liquidity
$515M
Runway
—
Shares 1y
+2%
Price & events
+125.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+2.3%
1D
+3.6%
1W
+16.4%
1M
+106.3%
3M
+111.4%
6M
+36.0%
1Y
+169.1%
2Y
+358.3%
5Y
+256.4%
All
Overview
- Market Cap
- $9.98B
- Volume
- 33.85K
- 52 Week Range
- $32.15 – $95.65
- Total Shares
- 107.35M
- Float Shares
- 89.94M
- Short %
- 10.39%
- % Held by Insiders
- 11.54%
- % Held by Institutions
- 75.57%
- RVOL
- 0.03x
- Beta
- 0.46
Pipeline stages · 5 programs
Relacorilant, Nab-paclitaxel, Gemcitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Miricorilant (Cohort A), Miricorilant (Cohort B)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Nenocorilant 200 mg, Nenocorilant 300 mg, Nenocorilant 400 mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Dazucorilant 300 mg, Dazucorilant 150 mg, Dazucorilant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Miricorilant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 8 trials · 6 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-09-15 | Phase 2 | Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kgorphan | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer | 270 | recruiting |
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | Miricorilant (Cohort A), Miricorilant (Cohort B) | Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH) | — | active not recruiting |
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 1/2 | Nenocorilant 200 mg, Nenocorilant 300 mg, Nenocorilant 400 mg | Neoplasms | — | recruiting |
| 2026-10 Estimated 50% readout ~2026-11-15 | Phase 2 | Dazucorilant 300 mg, Dazucorilant 150 mg, Dazucorilant | Amyotrophic Lateral Sclerosis | — | recruiting |
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | relacorilantorphan | Cushing Syndrome | — | active not recruiting |
Show all 8 trials · 3 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-09 Estimated 50% readout ~2027-10-16 | Phase 2 | Relacorilant, Nab-paclitaxel, Gemcitabineorphan | Adenocarcinoma, Carcinoma, Pancreatic Ductal | — | recruiting |
| 2026-05 | Phase 1 | Miricorilant | Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD) | 8 | recruiting |
| 2026-03-03 | Phase 1 | Miricorilant Treatment A, Miricorilant Treatment B, Miricorilant Treatment C, Miricorilant Treatment D | Healthy | 18 | completed |
Catalyst news & presentations · 14
- by the end of this yearGuided 40%chmp opinionCHMP (EU)relacorilant · EMA decision on MAA for relacorilant plus nab-paclitaxelSEC 8-K
- by the end of next yearGuided 40%readoutPhase 2dazucorilant · Results from MONARCH Phase 2b trialSEC 8-K
- by the end of this yearGuided 40%readoutPhase 2relacorilant · Phase 2 BELLA Part A trial results of relacorilant plus nab-paclitaxel and bevacizumabSEC 8-K
- by the end of this yearGuided 40%readoutPhase 2miricorilant · Phase 2b MONARCH trial results of miricorilant in MASHSEC 8-K
- 2026-07-29Estimated 45%earningsEarningsEarnings releaseyahoo
- July 11, 2026Confirmed 100%PDUFAPDUFArelacorilant · PDUFA date for NDA of relacorilant plus nab-paclitaxel in PROCSEC 8-K
- June 17, 2026regulatory submissionFiled (NDA/BLA)relacorilant · Resubmitted NDA to FDASEC 8-K
- April 2026conferencedata presentationsecondaryPhase 3relacorilant · Complete results from ROSELLA trial presented at SGO meetingSEC 8-K
- by early next yearreadoutResults from MOMENTUM trial on hypercortisolism prevalenceSEC 8-K
- by early next yearreadoutPhase 3relacorilant · Final overall survival results from ROSELLA trialSEC 8-K
- March 2026conferencedata presentationsecondaryOral presentation of MOMENTUM trial results at ACC meetingSEC 8-K
- 2025-12-31crlrelacorilant · FDA issued CRL for relacorilant NDA for hypercortisolism requiring additional evidence of effectivenessSEC 8-K
- December 30, 2025PDUFAPDUFArelacorilant · PDUFA target action date for relacorilant as treatment for hypercortisolism.SEC 8-K
- September 10, 2025filing acceptanceFiled (NDA/BLA)relacorilant · FDA accepted NDA for relacorilantSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 107,351,594 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $106 (+14% upside) · 3 analysts
- 2026-05-28HC Wainwright & Co.Buy
- 2026-05-28Canaccord GenuityBuy
- 2026-05-13UBSNeutral → Buy
- 2026-05-04HC Wainwright & Co.Buy
- 2026-05-01Piper SandlerOverweight
- 2026-03-26Canaccord GenuityBuy
Competitors — platinum-resistant ovarian cancer
- ASNDAscendis Pharma A/S$15.6B · D0
- IBRXImmunityBio, Inc.$7.8B · D5
- NUVBNuvation Bio Inc.$2.2B · D3
- STTKShattuck Labs, Inc.$523M · D6
- STROSUTRO BIOPHARMA, INC.$376M · D5
- ZNTLZentalis Pharmaceuticals, Inc.$334M · D5
- MGNXMACROGENICS INC$263M · D4
- GNLXGENELUX Corp$134M · D4
- CNTXContext Therapeutics Inc.$57M · D2
- GMABGENMAB A/S— · D1
Recent news
- 2026-07-23CORT Business Services Signs Agreement to Acquire Dwellworks Living, Expanding Its Position in Global Mobility and Temporary Living Solutions - Business Wire
- 2026-07-23Corcept Therapeutics to announce Q2 results on July 29 - scanx.trade
- 2026-07-22Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call - Yahoo Finance
- 2026-07-21Cort Hoge - On3
- 2026-07-21Cort Harold Amelung Obituary - The Press Democrat
- 2026-07-19Cort MacDonald Stats, Age, Position, Height, Weight, Fantasy & News - MLB.com
- 2026-07-18Cort McFadden Previews PBR's Upcoming Event In Oklahoma City - UFC.com
- 2026-07-18CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally - Stocktwits
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.